Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS).

We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions.

Key topics included:

Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept
The significance of ring sideroblasts and del(5q) in treatment selection
The management of anemia, thrombocytopenia, and neutropenia in MDS patients
The emerging role of imetelstat for heavily transfusion-dependent patients and its unique side effects

Join us as we unpacked the complexities of MDS treatment and emphasize the importance of personalized care for patients.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more insightful discussions in oncology!

Oncology Brothers: Recent Episodes

Oncology Brothers

MDS, #MyelodysplasticSyndrome, #RiskStratification, #OncologyBrothers

PancreaticCancer, #PartnersInPractice, #RASinhibitors, #OncologyBrothers

MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

MultipleMyeloma, #ENDURANCE, #Lenalidomide, #MRD, #OncologyBrothers

CARTtherapy, #MultipleMyeloma, #CRS, #ICANS, #OncologyBrothers

MultipleMyeloma, #CARTtherapy, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

MultipleMyeloma, #SmolderingMyeloma, #HemeMalignancy, #MRD, #OncologyBrothers

EHA2026, #Leukemia, #AML, #Myelofibrosis, #OncologyBrothers

DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers

TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers

BreastCancer #ASCO2026 #ClinicalTrials #PrecisionOncology #OncologyBrothers

MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers

MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs, #OncologyBrothers

KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI, #OncologyBrothers

GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

RadiationOncology, #SystemicTherapy, #SBRT, #MultidisciplinaryCare, #OncologyBrothers

ASCO2026, #GIOncology, #ctDNA, #FGFRinhibitor, #OncologyBrothers

PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

ASCO2026, #HeadAndNeckCancer, #Sarcoma, #GIST, #OncologyBrothers

EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers

AcuteMyeloidLeukemia, #MeninInhibitor, #FLT3Inhibitor, #Hematology, #OncologyBrothers

ChronicMyeloidLeukemia, #CML, #TreatmentFreeRemission, #OncologyBrothers

BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers

BRAFV600E, #NSCLC, #BRAFMEKinhibitor, #TargetedTherapy, #OncologyBrothers

MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers

LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers

LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

EarlyStageNSCLC, #CHECKMATE816, #NeoadjuvantTherapy, #PrecisionMedicine, #OncologyBrothers

SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers

ColorectalCancer, #SideEffectManagement, #DPYDtesting, #ChemotherapyToxicity, #SupportiveCare

ColorectalCancer, #MSIHigh, #BRAFV600E, #ctDNA, #GIOncology, #OncologyBrothers

PancreaticCancer, #KRASmutation, #NeoadjuvantTherapy, #SupportiveCare, #OncBrothers

BiliaryTractCancer, #Cholangiocarcinoma, #Immunotherapy, #BiomarkerTesting, #OncologyBrothers

CancerOfUnknownPrimary, #CUP, #NGS, #Immunohistochemistry, #OncologyBrothers

BladderCancer, #NMIBC, #MIBC, #Immunotherapy, #GU26, #OncologyBrothers

AIinHealthcare #Oncology #MedicalAI #CancerResearch #HealthcareInnovation #OncBrothers

KidneyCancer, #RenalCellCarcinoma, #GUASCO2026, #OncBrothers

ProstateCancer, #ADT, #PSMA, #PARPinhibitor, #OncologyBrothers

HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers

GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers

BladderCancer, #MIBC, #NMIBC, #Immunotherapy, #EVpembro

MultipleMyeloma, #MajesTEC3, #Teclistamab, #Daratumumab, #BispecificAntibody, #OncBrothers

TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers

TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers

HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers

MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers

EarlyBreastCancer, #OncotypeDX, #CDK46inhibitors, #OralSERD, #AdjuvantTherapy, #OncologyBrothers

Oncology #CancerTreatment #Immunotherapy #IL15Agonist #OncologyBrothers

HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers

AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

HeadAndNeckCancer, #HPV, #Immunotherapy, #MultidisciplinaryCare, #OncologyBrothers

OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART

OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast

ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology

SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25

BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers

SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC

ColorectalCancer #mCRC #TAS102 #Regorafenib #PalliativeCare #OncologyBrothers #GIOcology

HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

PI3Kinhibitors #BreastCancer #Hyperglycemia #ToxCheck #MetastaticBC #OncologyBrothers #TargetedTherapy

Anemia #IronDeficiency #Hemochromatosis #IronOverload #Hematology #Ferritin #OncologyBrothers

Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology

CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive

NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine